ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer by Pietrantonio, Filippo et al.
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional 
Repository 
 
 
 
 
 
This is the author's final version of the contribution published as: 
 
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 
Pietrantonio F*, Di Nicolantonio F*, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi 
A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim 
ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, 
Lazzari L,   Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, 
Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C. 
 
J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089. 
 
*corresponding authors 
 
 
 
 
The publisher's version is available at: 
 https://academic.oup.com/jnci/article-abstract/109/12/djx089/3860155 
 
When citing, please refer to the published version. 
 
 
Link to this full text:  
http://hdl.handle.net/ 
 
 
This full text was downloaded from iris-Aperto: https://iris.unito.it/  
1 
 
ALK, ROS1 and NTRK rearrangements define a new subtype of metastatic 
colorectal cancer  
 
1#Filippo Pietrantonio, 2,3#Federica Di Nicolantonio, 4Alexa B. Schrock, 5Jeeyun Lee,  
6Sabine Tejpar, 7Andrea Sartore-Bianchi, 8Jaclyn F. Hechtman, 9Jason Christiansen, 
 
3Luca Novara, 10Niall Tebbutt, 1Giovanni Fucà, 11,12Carlotta Antoniotti, 5Seung Tae Kim, 
 
9Danielle Murphy, 1Rosa Berenato, 1Federica Morano,  4James Sun, 9Bosun Min, 4Philip J. 
Stephens, 9Marissa Chen, 2,3Luca Lazzari,   4Vincent A. Miller, 9Robert Shoemaker, 7Alessio 
Amatu, 13Massimo Milione, 14Jeffrey S. Ross, 7,15Salvatore Siena, 2,3Alberto Bardelli, 
 
4Siraj M. Ali, 11,12Alfredo Falcone, 1,15Filippo de Braud and 11,12Chiara Cremolini 
 
Authors’ affiliations: 
1- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
Italy 
2- Department of Oncology, University of Torino, 10060 Candiolo (TO), Italy; 
3- Candiolo Cancer Institute-FPO, IRCCS, 10060 Candiolo (TO), Italy; 
4- Foundation Medicine, Inc., Cambridge, Massachusetts; 
5- Samsung Medical Center, Sungkyunkwan University School of Medicine, Kangnamgu, 
Seoul, Korea; 
6- Molecular Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; 
7- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.  
8- Memorial Sloan Kettering Cancer Center, New York, NY 
9- Ignyta Inc., San Diego, CA 
10- Austin Health, Melbourne VIC, Australia 
11- Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy 
12- University of Pisa, Pisa, Italy 
13- Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto 
Nazionale dei Tumori, Milan, Italy; 
14- Department of Pathology, Albany Medical College, Albany, NY 
15- Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Milan, 
Italy. 
 
 
 
 
2 
 
# Drs. Pietrantonio and Di Nicolantonio contributed equally to this article 
* To whom correspondence should be addressed: 
Dr Filippo Pietrantonio,  
Department of Medical Oncology, Medical Oncology Unit,  
Fondazione IRCCS Istituto Nazionale dei Tumori,  
Via Venezian 1, 20133 Milan, Italy 
Phone: + 39-0223903807 
E-mail: filippo.pietrantonio@istitutotumori.mi.it 
 
Dr Federica Di Nicolantonio 
Department of Oncology, University of Torino 
Strada Provinciale 142, Km 3.95 
10060 Candiolo, Torino, Italy 
Phone: +39-011-9933523 
Fax: +39-011-9933225 
E-mail: federica.dinicolantonio@unito.it 
 
Acknowledgment of research support for the study: 
This work was supported by Fondazione ARCO (Associazione Ricerche e Cure in Oncologia), Italy 
and partly supported by grants AIRC IG n. 17707 (F.D.N.); AIRC IG n. 16788 (A.B.); Fondo per la 
Ricerca Locale (ex 60%), Università di Torino, 2014 (F.D.N.); and grant Fondazione Piemontese 
per la Ricerca sul Cancro-ONLUS 5 per mille 2011 Ministero della Salute (A.B.). Investigators at 
Niguarda Cancer Center are supported by the following grants: Terapia Molecolare dei Tumori 
(A.S-B, S. S.) and Dynamic of Tumor Evolution & Therapy (A. S-B) from Fondazione Oncologia 
Niguarda Onlus; Associazione Italiana per la Ricerca sul Cancro (AIRC) 2010 Special Program 
Molecular Clinical Oncology 5x1000, project 9970 (S.S., A.B.). European Community’s grant 
agreement no. 635342-2 MoTriColor (A.B., S.S.). 
The Authors would like to thank Fabio Picchini for graphical support. 
 
Running head: ALK, ROS1 and NTRK rearranged metastatic colorectal cancer 
 
Number of tables/figures: 5 
 
 
 
 
3 
 
Abstract 
 
Background: ALK, ROS1 and NTRK fusions occur in 0.2%-2.4% of colorectal cancers. Pioneer 
cases of mCRC patients bearing rearrangements who benefited from anti-ALK, ROS, TrkA-B-C 
therapies were reported.  
Methods: Clinical features, molecular characteristics and outcome of 27 mCRC patients bearing 
ALK, ROS1, NTRK rearranged tumors were compared with those of a cohort of 319 patients not 
bearing rearrangements. Deep molecular and immunophenotypic characterizations of rearranged 
cases, including those described in the TCGA database, were performed. 
Results: Closely recalling the “BRAF history”, ALK, ROS1 and NTRK rearrangements more 
frequently occurred in elderly patients (p=0.024) with right-sided (p<0.001) and node-spreading 
(p=0.03), RAS wild-type (p<0.001), MSI-high (p<0.001) cancers. All patients bearing ALK, ROS1, 
and NTRK fusions had shorter overall survival (15.6 months) than negative patients (33.7 months), 
both in the univariate (HR 2.17, 95%CI 1.03-4.57; p<0.001) and multivariate models (HR 2.78, 
95%CI 1.27-6.07; p=0.011). All four evaluable patients with rearrangements showed primary 
resistance to anti-EGFRs. Frequent association with potentially targetable RNF43 mutations was 
observed in MSI-high rearranged tumors.  
Conclusion: ALK, ROS1, NTRK rearrangements define a new rare subtype of mCRC with 
extremely poor prognosis. Primary tumor site, MSI-high, RAS and BRAF status may help to identify 
patients bearing these alterations. While sensitivity to available treatments is limited, targeted 
strategies inhibiting ALK, ROS and TrkA-B-C provided encouraging results. 
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Genomic translocations leading to the constitutive activation of receptor tyrosine kinases (RTKs) 
play a crucial role in tumorigenesis across different malignancies, including colorectal cancer 
(CRC) 1,2. RTK fusions involving ALK, ROS1, and NTRK1-2-3 (NTRK) occur in 0.2%-2.4% of 
CRCs 3,4, and may represent new targets for therapeutic intervention 5-17. Addiction to kinase 
suppression or pharmacological inhibition has been reported in CRC preclinical models bearing 
RTK fusions, including the TPM3-NTRK1 rearranged KM12 cell line 18, the ALK rearranged cell 
line C10 19, patient-derived primary cell lines 10 and patient-derived xenografts 20. So far, a single 
heavily pre-treated metastatic CRC (mCRC) patient whose tumor bore an LMNA-NTRK1 fusion 
was treated with entrectinib, an oral selective inhibitor of ALK, ROS1, and TrkA-B-C (the protein 
products of the NTRK1-2-3 genes, respectively), with clinical benefit 15. Another mCRC patient 
whose tumor harbored STRN-ALK fusion received the oral ALK inhibitor ceritinib and achieved 
response 16, and a patient with a CAD-ALK rearrangement responded to entrectinib 6.  
Despite these pioneer case reports, it has not been clearly established whether ALK, ROS1, or NTRK 
rearranged tumors represent a distinct, although rare, disease subtype that should be detected early 
in order to adopt a tailored management strategy that may include targeted treatments.  
Although a few reports have described the occurrence of ALK, ROS1 and NTRK fusions in CRC 
(Supplementary Table 1), there is still limited knowledge about clinical and pathological 
characteristics, prognosis and sensitivity of these tumors to available treatments including anti-
EGFR monoclonal antibodies (MoAbs) such as cetuximab and panitumumab. Similarly, except for 
some preclinical reports 11,19, comprehensive molecular and functional data to clarify whether these 
alterations confer oncogene addiction and to suggest perspectives on optimal treatment strategies 
are not available yet. 
We therefore carried out a global effort aimed at characterizing the molecular and clinical landscape 
of ALK, ROS1 and NTRK rearranged mCRCs. Even though a broader list of gene fusions has been 
described in CRC, including those affecting RET, HER2 and BRAF 2,8,22,23, we specifically focused 
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on mCRC with ALK, ROS1 and NTRK rearrangements since their phylogeny is closely related and 
they are frequently grouped as targets of newly developed agents such as entrectinib 24.  
 
Methods 
Study design and participants 
In the clinical step (Figure 1), the cohort of 319 ALK, ROS1 and NTRK negative cases included 
patients screened for Ignyta’s phase 1 program at: Samsung Medical Center (SMC), Seoul, South 
Korea (n=209); Azienda Ospedaliero-Universitaria Pisana (AOUP), Pisa, Italy (n=79); Fondazione 
IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy (n=31). The population of 27 ALK, ROS1, 
NTRK rearranged mCRCs included patients collected at: Foundation Medicine Inc. (FMI), 
Cambridge, Massachusetts (n=12); Samsung Medical Center (SMC), Seoul, South Korea (n=4); 
Memorial Sloan Kettering Cancer Center (MSKCC), NYC, New York (n=3); Austin Health, 
Heidelberg, Australia (n=3) on behalf of MAX trial Investigators; Fondazione IRCCS Istituto 
Nazionale dei Tumori (INT), Milan, Italy (n=2); Niguarda Cancer Center (NCC), Milan, Italy 
(n=2); University Hospital Gasthuisberg (UHG), Leuven, Belgium (n=1). Molecular screening 
methods are detailed as Supplementary Methods and summarized in Figure 1. Study participants 
signed a written informed consent and the study was approved by the Institutional Review Board of 
INT, Milan. 
Statistical analysis 
We investigated the association of ALK, ROS1 and NTRK rearrangements with the following 
variables collected at the diagnosis of mCRC: age, gender, ECOG performance status (0, 1), 
primary tumor location (right colon, left colon, rectum), primary tumor resection, mucinous 
histology, time to metastases (synchronous, metachronous), number of metastatic sites (1, >1), 
metastatic sites (lung, lymph nodes, liver, peritoneum), RAS and BRAF status (mutated, wild-type), 
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MMR status (proficient, deficient). Fisher’s exact test, χ2 test or Mann-Whitney tests were used 
when appropriate to assess the associations of the ALK, ROS1, NTRK rearrangements with 
investigated characteristics. Statistical significance was set at p=0.05 for a bilateral test. 
We investigated the impact of ALK, ROS1 and NTRK rearrangements on overall survival (OS), 
defined as the time from diagnosis of metastatic disease to death or last follow up for alive patients. 
OS analysis was determined according to the Kaplan-Meier method and survival curves were 
compared using the log-rank test. The correlation of ALK, ROS1, NTRK status and 
clinicopathological characteristics with OS was assessed in univariate analysis. In order to minimize 
the bias of multiple comparisons, according to the false discovery rate correction, statistical 
significance was set at p=0.009 for a bilateral test. Cox proportional hazard model was adopted in 
the multivariate analysis, including as covariates variables correlated with survival with p<0.1 in the 
univariate analyses. Hazards’ proportionality was assumed. 
All analyses were carried out by means of Prism 7 for Mac OS X v7.0. 
Translational analyses 
As shown in Figure 1 and Supplementary Methods, NGS data were obtained through 3 different 
panels: FMI panel in 15 cases, Minerva panel (Ignyta Inc.®) in 11 cases, MSK-IMPACT panel in 1 
case. The association of individual samples with the type of translocation identified and NGS panel 
is shown in Supplementary Table 2. Finally, analysis in silico from TCGA data was performed 
(Supplementary Methods). 
 
Results 
Study population 
Based on a systematic literature review, we identified 24 published cases of ALK, ROS1 or NTRK 
rearranged CRCs (Supplementary Table 1). Nineteen were staged as metastatic, and informative 
medical records were retrieved for fifteen of them. Taking advantage of screening programs 
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worldwide, we were able to identify 12 additional cases. Therefore, the final population consisted of 
27 ALK, ROS1, NTRK rearranged mCRCs (Figure 1; Supplementary Table 2) including a newly 
described SCYL3-NTRK1 fusion (Supplementary Figure 1). We compared the clinical and 
pathological features of ALK, ROS1, and NTRK rearranged mCRCs with a cohort of ALK, ROS1, 
and NTRK negative patients (n=319), screened for phase 1 studies at three Institutions (Figure 1). 
The overall incidence of ALK, ROS1, or NTRK rearrangements at these Institutions was 1,5% (5 out 
of 324 screened samples).   
Clinical and pathological features of ALK, ROS1 and NTRK rearranged mCRC 
As shown in Table 1, rearrangements were more frequent in older patients (p=0.024) with right-
sided tumors (80.0% vs 30.0%; p<0.001), and spread more frequently to lymph nodes (45.8% vs 
24.7%; p= 0.030) and less frequently to the liver (41.7% vs 65.5%; p=0.026). Additionally, 
although only 50% of patients in the control group had available information on MSI status, a 
higher percentage of tumors bearing rearrangements were MSI-high (48.1% vs 8.1%; p<0.001).  
Of note, RAS mutations were much less frequent in rearranged than in other tumors (7.4% vs 
48.3%; p<0.001). Only one (3.7%) rearranged sample showed the co-occurrence of SLC34A2-ROS1 
fusion and BRAF V600E mutation. Overall, right-sided primary location, RAS wild-type and MSI-
high status, in addition to female gender, were particularly associated with NTRK rearrangements. 
Notably, patients with right-sided, RAS and BRAF wild-type, MSI-high mCRCs had 54- and 453-
fold higher chances of harboring ALK, ROS1, or NTRK rearrangements (OR=54.0, 95% CI: 13.3-
219.1; p<0.001) or specifically NTRK rearrangements (OR=453.0, 95% CI: 67.2-3053.4; p<0.001), 
respectively. These four easy to collect characteristics (primary tumor site, MSI, RAS and BRAF 
status) enable identification of patients bearing an ALK, ROS1, or NTRK rearrangement with 
positive and negative predictive values of 75% and 95%. The positive and negative predictive 
values with specific regard to NTRK rearrangements were 75% and 99%.  
Molecular features of ALK, ROS1 and NTRK rearranged CRC 
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Molecular reports from next-generation sequencing DNA analyses performed on rearranged cases 
were retrieved (Figure 1). Additionally, molecularly annotated genomic variants from seven CRC 
samples harboring ALK or NTRK3 fusions (Supplementary Figure 2 and 3) in the TCGA database 
were gathered. First, we focused on the subset of genes previously reported as the most frequently 
mutated in CRCs (Figure 2A) 23 . In line with previous reports regarding MSI-high BRAF mutated 
CRC 24-26, MSI-high rearranged tumors were enriched for alterations affecting RNF43 (64.7% vs 
5.9%; p=0.0004 Fisher’s exact test), most of which were frameshift changes affecting glycine 659, 
which lies within a mononucleotide repeat (Figure 2A).  
A low prevalence of RAS/BRAF mutations, also accounting for MSI-high status (Figure 2B), was 
reported. Only one MSS rearranged tumor displayed a BRAF V600E mutation, while two MSI-high 
rearranged mCRC samples carried BRAF alterations (I371M and K475R) of unknown significance 
and two MSS rearranged CRCs showed a well-established oncogenic variant (G469A), and an 
alteration (D594H) that impairs BRAF kinase activity but paradoxically activates MEK and ERK 
through transactivation of CRAF, respectively. The prevalence of PIK3CA mutations in CRCs 
carrying rearrangements (12.1%) did not significantly differ from what reported in unselected 
colorectal tumors 23. 
An explorative analysis of selected genes implicated in immune-escape mechanisms 27 was 
conducted by retrieving the transcriptomic profiles of the seven rearranged samples for which RNA 
seq data was available from the TCGA and these were compared with non rearranged MSI-high 
CRC samples also from TCGA (Figure 2C). Although the analysis suggested that the presence of 
rearrangements did not impact the typical MSI-high phenotype represented by the upregulation of 
immunoinhibitory molecules 27, the small number of samples limits the power of this observation.   
Prognostic impact of ALK, ROS1 and NTRK rearrangements in mCRC 
Finally, we explored the clinical impact of ALK, ROS1 and NTRK rearrangements in the metastatic 
setting (TCGA samples were excluded from survival analyses, since they were mostly found in 
earlier disease stages and had incomplete follow-up data). When looking at OS results, at a median 
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follow-up of 28.5 months [95%CI 23.8-36.9], patients bearing ALK, ROS1 or NTRK rearranged 
tumors had poor prognosis when compared with rearrangement negative tumors (median OS: 15.6 
[95%CI 10.0-20.4] versus 33.7 [95%CI 28.3-42.1] months; HR for death: 2.17, 95% CI 1.03-4.57; 
p<0.001) (Figure 3A). When applying the false discovery rate correction, the association of ALK, 
ROS1 and NTRK rearrangements with OS was still statistically significant (p<0.005). In the 
multivariable model (Table 2) including other covariates associated with OS with p<0.1 (age, 
primary tumor location, primary resection, BRAF mutation and MSI status), the presence of gene 
rearrangements was still associated with shorter OS [HR for death: 2.33, 95% CI 1.10-4.95; 
p=0.020]. Notably, patients with ALK, ROS1 or NTRK rearranged tumors had short OS 
independently from MSI status (Figure 3B). In fact, median OS was 17.0 (95% CI 10.0-31.4) 
months for patients with MSS rearranged tumors and 15.6 (95% CI 10.0-20.4) months for MSI-high 
ones. Moreover, the poor prognostic impact of gene rearrangements was independent of primary 
tumor location: both in right- and left-sided tumors patients bearing rearrangements had shorter OS 
than those with negative tumors (Supplementary Figure 4). 
Therapeutic implications of ALK, ROS1 and NTRK rearrangements in mCRC 
All the patients with rearranged tumors that were treated with cetuximab or panitumumab (N=4) 
experienced disease progression as best response during the treatment with anti-EGFR agents 
(Supplementary Methods; Supplementary Figure 5).  
One patient with EML4-ALK rearrangement and MSI-high tumor received single agent anti-PD-1 
treatment with nivolumab and achieved a durable response (Supplementary Figure 5). Notably, the 
IHC staining of this tumor revealed intense staining for CD4, CD8, CD68 and especially PDL-1, 
with an abundant intra and extratumoral lymphocytic infiltration (Supplementary Figure 6).  
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Discussion 
Here we showed that ALK, ROS1 and NTRK rearrangements identify an uncommon CRC molecular 
subtype with specific clinical, pathological and molecular features. The investigated fusions (and 
particularly those affecting NTRK) were more frequent in elderly females with right-sided tumors, 
spreading to extra-regional lymph nodes. However, the most clinically relevant association was 
found with MSI-high and RAS wild-type status, which are two relevant and commonly used 
biomarkers for patient selection for immunotherapy and anti-EGFRs, respectively. This type of 
clinical and molecular associations resemble very closely what observed for codon 600 BRAF 
mutations and, interestingly, BRAF V600 mutations and gene fusions were almost invariably 
mutually exclusive. Since MSI-high status is reported in less than 5% of mCRCs 28, the frequency 
of MSI-high rearranged tumors is unexpectedly high (48.1%), even considering the right-sided 
location 29. The frequency of MSI-high status in ALK, ROS1 and NTRK rearranged tumors seems 
similar or even higher than in BRAF V600E mutated mCRCs, where it reaches 30-35% 24,28. While 
the association between right-sided tumors, MSI-high and BRAF mutations is well established, we 
report for the first time a strong association with right-sided tumor location and MSI-high status 
also for gene fusions. Of note, while frame-shift mutations occurring in MSI-high cancers are 
heterogeneously represented in tumor sub-clones30, gene rearrangements appear as “founder” 
events, as they are present in most, if not all, tumor cells. Nevertheless, since defective mismatch 
repair is also an early event in CRC carcinogenesis, the adenoma-carcinoma sequence should be 
further elucidated for this rare subtype., Future studies exploring the role of food carcinogens and/or 
peculiar microbiota components in the right colon are also warranted to clarify the potential link 
between MSI status and kinase rearrangements. 
When compared with negative samples, ALK, ROS1, and NTRK rearranged tumors show a low 
frequency of RAS and BRAF oncogenic mutations. A low prevalence of BRAF V600E mutation 
was reported in the group of negative tumors (5.8%), probably as a consequence of the poor 
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prognosis and rapid progression of BRAF mutant tumors, preventing these patients to receive later 
lines of therapy and therefore to be screened for phase 1 trials. Therefore, we were unable to 
identify a statistically significant difference in terms of BRAF mutations between rearranged and 
not rearranged tumors (p=1.000) in the present series. However, the observation that ALK, ROS1 
and NTRK rearrangements co-occur rarely with other common driver events in the RTK-RAS 
pathway, and specifically RAS and BRAF codon 600 mutations, supports the hypothesis that gene 
fusions drive oncogene addiction. Indeed, previous reports indicate that NTRK1 and ALK rearranged 
CRC preclinical models and patients respond to pharmacological blockade of the fusion kinase 
6,11,15,19,20
. In spite of the relatively low prevalence of gene fusions, the identification of patients 
with tumors bearing these alterations may be simplified and enriched by the evaluation of four 
simple and easy-to-collect variables (i.e. primary tumor location, RAS, BRAF and MSI-high status), 
which are available for the vast majority of patients. Therefore, in an evidence-based perspective of 
resource sparing, the molecular screening for gene rearrangements should not be denied to patients 
with RAS and BRAF wild-type and/or MSI-high mCRC. 
A high prevalence of RNF43 frameshift mutations was reported among ALK, ROS1 and NTRK 
rearranged tumors, though in the absence of concomitant BRAF V600E mutations, thus suggesting 
that gene rearrangements may act as driver events alternative to BRAF in the tumorigenesis of MSI-
high right-sided tumors carrying RNF43 alterations. Since porcupine inhibitors are being developed 
to suppress paracrine WNT-driven growth of RNF43 mutant tumors 
(https://clinicaltrials.gov/ct2/show/NCT02278133), our findings may provide a rationale for co-
targeting tyrosine kinase oncogenic fusions as well as the WNT pathway in this rare tumor subset. 
Closely recalling the long “BRAF history”, we found that gene fusions occurring in mCRCs are 
associated with unfavorable outcome. However, it must be pointed out that patients with MSI-high 
mCRCs have worse OS independently from the co-occurrence of BRAF V600E mutation 28. 
Therefore, given the association of ALK, ROS1 or NTRK rearrangements with MSI-high status and 
the mutual exclusivity with codon 600 BRAF mutations, our findings may partly explain the 
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aggressive behaviour of MSI-high BRAF wild-type mCRCs. The same observations are true for the 
potential contribution of gene fusion to the poor prognosis of some right-sided mCRCs 31.  
Again, consistent with previous findings regarding BRAF V600E mutations 32, ALK, ROS and 
NTRK rearranged tumors seem not to derive benefit from anti-EGFR monoclonal antibodies,, thus 
confirming preclinical observations 19. Given the very low frequency of gene fusions in mCRC, the 
validation of this finding is quite unrealistic. However, these results are supported by a strong 
biologic rationale and may contribute to explain – at least in part - the limited activity of anti-
EGFRs in right-sided, RAS and BRAF wild-type tumors 33. From a clinical perspective, it seems 
therefore reasonable to offer an intensive first-line regimen, such as the triplet FOLFOXIRI plus 
bevacizumab to patients with right-sided, ALK, ROS1, and NTRK rearranged mCRCs 34, based on 
their aggressive behaviour, and in line with current recommendations for BRAF V600E mutant 
tumors.  
Our observations argue that the early enrolment of patients with tumors bearing ALK, ROS1 and 
NTRK rearrangements in clinical trials with matched targeted agents should be highly encouraged, 
as this subset of patients may in fact be uniquely poised to benefit from targeted strategies. 
Nevertheless, benefit from targeted strategies against ALK, ROS1, and TrkA-B-C may be transient 
and mechanisms of acquired resistance may occur early 17,20. This is quite reasonable particularly 
when considering the impressive mutational burden of MSI-high tumors that may promote in these 
tumors the early emergence of acquired resistance.  
The combination of targeted agents and immunotherapy approaches in MSI-high rearranged tumors 
may be a promising strategy to be further investigated, supported by a strong molecular rationale, 
and by the absence of impact of rearrangements on MSI-high associated immunophenotype.   
The major limitation of this study is the choice of the control group. Although a wider series of 
negative cases, especially those analyzed by MSK-IMPACT or FoundationOne tests, would have 
been more appropriate, both MSK-IMPACT and FoundationOne are DNA-based assays and do not 
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completely cover intronic regions, thus making possible to miss some gene fusions. Moreover, 
clinical data were not available for the vast majority of these patients. Therefore, a cohort of well-
annotated patients screened at three Institutions for a phase 1 trial and quite representative of the 
general population of mCRC patients was adopted as control group. 
In conclusion, the features of ALK, ROS1 and NTRK rearrangements are somewhat reminiscent of 
the peculiar traits previously recognized in BRAF V600E mutant mCRC. These fusions define a 
new molecular subtype of mCRC associated with poor prognosis, whose recognition allows a 
proper tailored management for a new subgroup of patients. The large-scale diffusion of this 
assessment may be eased by the availability of a multi-step procedure for the detection of gene 
fusions, starting from a simple IHC test with high sensitivity, or a comprehensive approach able to 
identify ALK, ROS1, and NTRK rearrangements, as well as other potentially targetable kinase 
fusions 22. Finally, while the poor prognosis of rearranged tumors may suggest the adoption of 
upfront intensive treatments when feasible, new targeted strategies are under investigation and the 
high prevalence of MSI-high status in rearranged tumors opens the way to evaluate new 
combination approaches, including targeted (ALK, ROS1, TrkA-B-C) and immunotherapy agents.  
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Table 1. Patients’ characteristics according to the presence or absence of ALK, ROS1, NTRK rearrangements, or specifically for presence or absence of NTRK and ALK 
rearrangements. 
Characteristics 
ALK, ROS1, NTRK 
negative 
(N=319) 
N (%) 
ALK, ROS1, NTRK 
rearranged 
(N=27) 
N (%) 
p* 
NTRK 
rearranged  
(N=13) 
N (%) 
pΏ 
ALK 
rearranged  
(N=11) 
N (%) 
pΐ 
 Sex 
 
Female 129 (40.4) 18 (66.7) 
0.159 
9 (69.2) 
0.047 
7 (63.6) 
0.211 
 Male 190 (59.6) 9 (33.3) 
4 (30.8) 
 
4 (36.4) 
 Age Median 57 64 
0.024 
68 
0.032 
55 
0.967 
 Range 15-88 40-62 33-73 40-87 
 ECOG PS 0 106 (33.4) 9 (64.3) 
0.250 
2 (25.0) 
1.000 
3 (75.0) 
0.115  1-2 211 (66.6) 5 (35.7) 6 (75.0) 1 (25.0) 
 NA 2  13 5 7 
 Primary tumor location Right colon 98 (31.0) 20 (80.0) 
<0.001 
10 (90.9) 
<0.001 
8 (72.7) 
 
0.014 
 
 Left colon 125 (39.6) 3 (12.0) 0 2 (18.2) 
 Rectum 93 (29.4) 2 (8.0) 1 (9.1) 1 (9.1) 
 NA 3 2 2 0 
 Mucinous histology Yes 40 (12.7) 1 (5.9) 0.706 0 0.602 1 (11.1)  
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 No 276 (87.3) 16 (94.1) 8 (100.0) 8 (88.9) 1.000 
 NA 3  10 5 2 
Primary tumor resected Yes 240 (75.2) 19 (86.4) 
0.308 
8 (72.7) 
1.000 
0 
<0.001  No 79 (24.8) 3 (13.6) 3 (27.3) 8 (100.0) 
 NA 0 5 2 3 
 Time to metastases Synchronous 210 (66.2) 11 (64.7) 
 
5 (62.5) 
1.000 
6 (75.0) 
0.723 
 Metachronous 107 (33.8) 6 (35.3) 
1.000  
3 (37.5) 
2 (25.0) 
 NA 2 10  5 3 
 Number of metastatic sites 1 161 (50.9) 14 (58.3) 
0.531 
7 (63.6) 
0.544 
6 (54.5) 
1.000  >1 155 (49.1) 10 (41.7) 4 (36.4) 5 (45.5) 
 NA 3 3 2 0 
 Lung metastases Yes 129 (40.8) 5 (20.8) 
0.053 
0 
1.000 
4 (36.4)  
 No  187 (59.2)  19 (79.2) 11 (100.0) 7 (63.6) 1.000 
 NA 3 3 2 0  
 Lymph Nodes metastases Yes 78 (24.7) 11 (45.8)  
0.030 
 
7 (63.6) 
0.008 
3 (27.3)  
  No 238 (75.3) 13 (54.2) 4 (36.4) 8 (72.7) 0.737 
 NA 3 3 2 0  
Liver metastases Yes 207 (65.5) 10 (41.7) 
0.026 
4 (36.4) 
0.058 
5 (45.5)  
0.204  No 109 (34.5) 14 (58.3) 7 (63.6) 6 (54.5) 
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 NA 3 3 2 0 
 Peritoneal metastases Yes 89 (28.2) 8 (33.3) 
0.640 
5 (45.5) 
0.306 
3 (27.3)  
  No 227 (71.8) 16 (66.7) 6 (54.5) 8 (72.7) 1.000 
 NA 3 3 2 0  
 RAS status wild-type 155 (51.7) 25 (92.6)  
<0.001 
 
11 (84.6) 
<0.001 
9 (81.8) 
0.065  mutated 145 (48.3) 2 (7.4) 2 (15.4) 2 (18.2) 
 NA 19 0 0 0 
 BRAF status wild-type 258 (94.2) 26 (96.3) 
1.000 
13 (100.0)  
1.000 
 
11 (100.0) 
1.000   V600E mutated 16 (5.8) 1 (3.7) 0 0 
 NA 45 0 0 0 
MSI status MSS 148 (91.9) 14 (51.9) 
<0.001 
3 (23.1)  
<0.001 
 
4 (36.4) 
<0.001  MSI-high 13 (8.1) 13 (48.1) 10 (76.9) 7 (63.6) 
 NA 158 0 0 0 
NA: not available. *Comparison of ALK, ROS1, NTRK rearranged versus not rearranged tumors; ΏComparison of NTRK rearranged versus not rearranged tumors; ΐComparison of ALK 
rearranged versus not rearranged tumors. ROS1 rearranged tumors were not separately analyzed because of the small sample size (N=3) 
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Table 2. Association of ALK, ROS, NTRK rearrangements and known prognostic baseline characteristics with OS 
Characteristics 
 
N 
Univariate analyses Multivariable model 
HR 95% CI p HR 95% CI p 
ALK, ROS, NTRK status Negative 316 1 - - 1 - - 
 Rearranged 20 2.17 1.03-4.57 <0.001 2.33 1.10-4.95 0.020 
Age - 336 1.04 1.02-1.05 <0.001 1.04 1.02-1.07 <0.001 
 ECOG PS 0 112 1 - - - - - 
 1-2 216 1.01 0.72-1.42 0.950 - - - 
 Primary tumor site Left 
colon/Rectum 
221 1 - - 1 - - 
 Right colon 113 1.41 1.01-2.00 0.038 1.11 0.62-1.98 0.733 
 Mucinous histology No 290 1 - - - - - 
 Yes 41 0.97 0.59-1.58 0.885 - - - 
 Primary resection Yes 257 1 - - 1 - - 
 No 82 1.51 1.01-2.29 0.024 1.69 0.94-3.05 0.079 
Time to metastases Metachronous 113 1 - - - - - 
 Synchronous 220 1.24 0.88-1.74 0.242 - - - 
Number of metastatic sites 1 171 1 - - - - - 
 >1 164 1.28 0.93-1.77 0.134 - - - 
RAS status Wild-type 173 1 - - - - - 
 Mutated 147 1.31 0.94-1.82 0.117 - - - 
BRAF status Wild-type 275 1 - - 1 - - 
 Mutated 17 2.20 0.97-4.95 0.058 0.91 0.35-2.38 0.855 
 MSI status MSS 156 1 - - 1 - - 
 MSI-high 22 2.28 1.09-4.76 0.005 1.42 0.63-3.21 0.397 
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Figure Legends 
 
Figure 1. Study flow-chart.  
Top: A total of 27 metastatic colorectal cancer (mCRC) cases with ALK (n=11), ROS1 (n=3) and 
NTRK (n=13) translocations were collected. Patients were retrieved by: Ignyta’s phase 1 screening 
program in Italy, Belgium and South Korea; MAX trial’s post-hoc analysis conducted in Australia; 
Foundation Medicine Inc. (FMI) dataset in USA; Memorial Sloan Kettering-Integrated Mutation 
Profiling of Actionable Cancer Targets (MSK-IMPACT) screening program in USA. Bottom left: 
Clinicopathological characteristics, RAS and BRAF status, Mismatch-repair (MMR) status, survival 
and treatment outcome data in the ALK, ROS1, NTRK rearranged population (n=27) were compared 
with those from a cohort of ALK, ROS1, NTRK negative mCRC patients (n=319) included in 
Ignyta’s phase 1 screening program. Bottom right: Annotated genetic variants were retrieved from 
targeted next-generation sequencing analyses of tumor samples  (N=27) from ALK, ROS1, NTRK 
rearranged mCRC patients. The number of samples analyzed by different gene panels is shown. 
Analysis of publicly available RNA sequencing data from the TCGA COADREAD (colorectal) 
study allowed the identification of 7 additional tumors carrying ALK or NTRK3 translocations. 
Molecular annotations from TCGA translocated tumors were pooled with those from mCRC 
patients to increase power of detecting genetic alterations co-existing with ALK, ROS1, NTRK 
rearrangements.  
Figure 2. Molecular profile of ALK, ROS1, NTRK rearranged colorectal cancer. A. OncoPrint 
map depicting alterations in top mutated colorectal cancer genes in ALK, ROS1, NTRK rearranged 
cancers (27 cases from this study and 7 samples from TCGA23). Individual sample cases are 
designated by columns (top) and grouped by MMR status, while individual genes are presented by 
rows. B. Gene mutation profiles, excluding silent mutations, were compared between ALK, ROS1, 
NTRK rearranged cancers (27 cases from this study and 7 samples from TCGA) and data previously 
reported in a large-scale sequencing study of unselected CRC25. Grey bars indicate the number of 
samples that were not sequenced for the indicated genes. C. Expression (RNA sequencing data) of 
selected genes implicated in immunoevasion (gene list was obtained from25) in ALK or NTRK3 
rearranged tumors identified in TCGA, grouped based on their MMR status. The average 
expression of non-rearranged TCGA MSI-high CRC samples (n=92) from TCGA is also shown. 
Figure 3. Survival in metastatic colorectal cancer patients carrying ALK, ROS1, NTRK 
rearranged tumors.  Panel A: Kaplan-Meier curves for overall survival (OS) in patients with ALK, 
ROS1, NTRK rearrangements (n=20; red line) as compared to those with ALK, ROS1, NTRK 
negative tumors (n=316; blue line). Panel B: Kaplan-Meier curves for overall survival (OS) in 
patients with ALK, ROS1, NTRK rearrangements and MMR proficient status (n=11; red line) or 
patients with ALK, ROS1, NTRK rearrangements and MMR deficient status (n=9; green line) as 
compared to those with ALK, ROS1, NTRK negative tumors (n=316; blue line). 
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Supplementary Methods 
 
Patients screening and translational analyses 
1 - STARTRK1 phase 1 study by Ignyta®. In the first step, all screened samples were submitted to 
Immunohistochemistry (IHC) staining, as previously described 1. Briefly, a cocktail of antibodies 
targeted to the C-terminal domains of pan-Trk (including TrkA, TrkB, TrkC, Cell Signaling, clone 
C17F1, 1:25 dilution), ROS1 (Cell Signaling, clone D4D6, 1:500 dilution) and ALK (Cell 
Signaling, clone D5F3, 1:500 dilution) was used with a single diaminobenzidine (DAB) reporter 
system.  The presence of staining indicates the elevation of expression for at least one of the 
proteins targeted by the antibody cocktail.  In the second step, all samples scored positive for IHC 
staining were tested by RNA-based next generation sequencing to determine the presence/absence 
of a gene fusion.  The presence and nature of gene rearrangements/fusions was determined by RNA 
sequencing using a method previously described 1.  Total nucleic acid (a combination of both DNA 
and RNA) was isolated from FFPE tissues (Agencourt, Beckman) and sequencing libraries were 
generated using an anchored multiplex PCR (AMP) method 1,2.  RNA quality and amplifiable 
ability of the extracted material was assessed as previously described 1. Briefly, the PreSeq RNA 
QC assay, which uses qPCR analysis of the housekeeping gene, VCP was performed on all 
samples.  The RNA quality assessment was used to determine the potential for a false negative 
result from specimens where the RNA was fragmented to a degree that a gene rearrangement could 
not be amplified or mapped reliably. Sequencing was performed on the Illumina MiSeqDx platform 
(Illumina, San Diego, CA).   
For patients screened at Ignyta, DNA next generation sequencing (NGS) analysis was performed 
through the custom “Minerva” panel, which interrogated 263 genes resumed in the list below: 
ABL1 BRIP1 CHEK2 ERG GLI1 IHH MET NTF4 RUNX1 TSC2 
AKT1 BTC CHMP2A ESR1 GNA11 IKZF1 MIB1 NTRK1 RUNX1T1 TYRO3 
AKT2 BTK CREBBP EZH2 GNAQ IL12A MKI67 NTRK2 SDHB VCAM1 
AKT3 CAD CRKL FANCA GPI IL12B MLH1 NTRK3 SETD2 VCP 
ALDH1A1 CBFB CSF1R FANCB GSK3B IRF1 MPL PALB2 SHH VEGFA 
ALK CCL2 CSF3R FANCC GTSE1 IRS2 MS4A1 PDCD1 SMAD4 VHL 
AMER1 CCL5 CTLA4 FANCD2 GZMA JAG1 MSH2 PDGFRA SMO VIM 
APC CCND1 CTNNB1 FANCF GZMB JAK1 MSH6 PDGFRB SNAI1 WNT1 
AR CCND2 CX3CL1 FANCG GZMH JAK2 MTOR PIK3CA SOX2 WNT10A 
ATAD2 CCND3 CXCL10 FANCI HBEGF KDR MYC PIK3CG SOX9 WNT10B 
ATM CD22 CXCL11 FANCL HDAC1 KEAP1 MYCN PIK3R1 SRC WNT2B 
ATR CD274 CXCL9 FANCM HDAC4 KIT MYD88 PMS2 STAT3 WNT3 
AURKA CD3D CXCR3 FAS HES1 KMT2A NANOG PRKCG STAT6 WNT4 
AXIN1 CD4 CXCR4 FBXW7 HGF KRAS NF1 PRKCI STK11 WNT5A 
AXIN2 CD47 DBF4 FGF23 HNF1A LAG3 NF2 PTCH1 SYK WNT7A 
AXL CD68 DDR2 FGFR1 HOXA9 LNX2 NFE2L2 PTEN TBX21 WNT8A 
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BAP1 CD79B DOT1L FGFR2 HRAS LYN NFKBIA RAB7A TCF3 WNT9A 
BARD1 CD8A EGF FGFR3 ICAM1 MAP2K1 NGF RAD50 TCF4 WNT9B 
BCL2 CDC7 EGFR FGFR4 IDH1 MAP2K2 NGFR RAD51 TCF7L2 WT1 
BCL6 CDH1 EP300 FH IDH2 MAP2K4 NKX2-1 RAF1 TGFA XPO1 
BDNF CDH2 EPGN FLT1 IDO1 MAPK1 NOTCH1 RALA TGFBR2 
BRAF CDK4 EPHA2 FLT3 IFNG MAPK3 NOTCH2 RALB TNFRSF4 
BRCA1 CDK6 EPHA3 FLT4 IGF1 MCL1 NOTCH3 RARA TNIK 
BRCA2 CDKN1B ERBB2 FOXP3 IGF1R MCM2 NPM1 RB1 TOP1 
BRD3 CDKN2A ERBB3 GAS6 IGF2 MDM2 NRAS RET TOP2A 
BRD4 CEBPA ERBB4 GATA3 IGF2R MEN1 NRG1 RNF43 TP53 
BRDT CHEK1 EREG GATA6 IGFBP1 MERTK NTF3 ROS1 TSC1 
 
2 - Retrospective translational study of the Australian MAX trial, as previously described 3. 
3 - Samples tested by Foundation Medicine were assayed with a validated comprehensive genomic 
profiling (CGP) platform during the course of clinical care at the request of the treating physician. 
DNA was extracted from 40 microns of FFPE sections, and CGP was performed on hybridization-
captured, adaptor ligation based libraries to a mean coverage depth of >650X for 236 or 315 cancer-
related genes plus select introns from 19 or 28 genes frequently rearranged in cancer as described 
previously 4. All classes of genomic alterations (GA) were identified including base pair 
substitutions, insertions/deletions, copy number alterations, and rearrangements. Microsatellite 
instable (MSI-H) or stable (MSS) status as a measure of mismatch repair deficiency was determined 
using a proprietary computational algorithm. Tumors were classified as microsatellite instable 
(MSI-H) or microsatellite stable (MSS) using a principal component 1 cutoff value of less than -8.5 
or greater than -4, respectively 5. 
4 - Samples tested by Memorial Sloan Kettering Cancer Center underwent analysis by the clinically 
validated MSK-IMPACT assay. This hybridization-based next generation sequencing assay 
interrogates all exons and select introns and promoters of over 340 cancer-related genes. Tumor 
samples are sequenced against matched normal samples and only somatic alterations including 
structural variants, mutations, and copy number alterations are reported. Further details about this 
assay have been published by Cheng et al. 6. 
 
In silico analysis of the TCGA data (ALK, ROS1, NTRK fusion search in TCGA-COAD-
READ) 
FPKM-normalized transcriptomic profiles were downloaded from the Genomic Data Commons 
Data Portal (https://gdc-portal.nci.nih.gov) for the tumor samples in the TCGA-COAD and TCGA-
READ datasets and the z-score for each gene was calculated. Tumors in the 95th percentile for ALK, 
NTRK1, NTRK2, NTRK3 or ROS1 gene expression were selected for further analyses, since outlier 
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kinase expression is often driven by fusion transcripts 7,8. For the 154 tumor samples carrying 
outlier expression in one of the selected kinases (as shown in Supplementary Fig. 2 and listed in 
Supplementary Table 4), RNAseq reads were downloaded from the Genomic Data Commons Data 
Portal. Reads were aligned using the BWA-mem 9 algorithm to hg19 human reference genome, then 
all the non-perfect alignments falling on the genes of interest were selected and aligned using 
BLAT 10 with tileSize=11 and stepSize=5. The resulting alignment was post-processed to detect 
chimeric alignments, by applying the following criteria: i) each fusion partner must have at least 15 
nucleotides mapped of the respective end of the read; ii) the two parts of the read must map to 
different genes; iii) at least one of the two fusion breakpoints must be on the exon boundary. Due to 
the short read length (ranging from 48 to 76, Supplementary Table 4), it was not possible to impose 
a threshold on the number of reads supporting each fusion breakpoint. After the first gene-specific 
analysis, we did a cross-validation on the entire transcriptome using FusionMap11. In addition to the 
six fusion transcripts found on selected genes using our custom-built pipeline, FusionMap was able 
to identify also a previously reported VPS18-NTRK3 translocation12. 
 
Characterization of the novel SCYL3-NTRK1 fusion 
For Patient #13 harboring the novel fusion, SCYL3-NTRK1, a set of PCR primers was generated to 
further confirm the result (SCYL3: 5’- GGAGGAGAACGAACCAAGAT; NTRK1: 5’-
CATGAAATGCAGGGACATGG).  Total nucleic acid was reverse-transcribed and amplified by 
PCR using SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity 
(ThermoFisher, Carlsbad, CA). The PCR products were assessed on a 2100 Bioanalyzer 
electrophoresis system (Agilent, Santa Clara, CA).  A parallel no template control was also included 
to determine the presence of any background hybridization. 
 
Criteria for evaluation of primary resistance to anti-EGFR monoclonal antibodies 
To assess the association of ALK, ROS1 and NTRK status with primary resistance to anti-EGFR 
MoAbs, we restricted the analysis to RAS and BRAF wild-type patients receiving cetuximab or 
panitumumab as single agents or in combination with irinotecan, only in strictly defined irinotecan-
refractory patients (i.e. those with documented disease progression during or within three months 
from the last irinotecan-containing therapy). We excluded patients receiving an anti-EGFR agent in 
combination with chemotherapy, except in the case of disease progression as best response 
indicating primary resistance to the whole treatment. Thus, we were able to focus on the true impact 
of ALK, ROS1 and NTRK translocations on treatment resistance. 
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Supplementary Table S1. ALK, ROS1, NTRK rearranged cases described in the literature. 
Reference NTRK fusions N=9 
ALK fusions 
N=13 
ROS1 fusions 
N=2 Retrieved case 
Lin et al, 2009 [2]  EML4-ALK  No 
 EML4-ALK  No 
Lipson et al, 2012 [3]  C2orf44-ALK  No 
Aisner et al, 2014 [4] 
 EML4-ALK  Yes 
  SLC34A2-ROS1 Yes 
  Unknown-ROS1 Yes 
Houang et al, 2015 [5]  PPP1R21–ALK 
 No, stage II 
Créancier et al, 2015 [6] TPR-NTRK1   No, stage II TPM3-NTRK1   No, stage II 
Lee J et al, 2015 [6]  CAD-ALK  Yes 
 EML4-ALK  Yes 
Sartore Bianchi et al, 2015 [7] LMNA-NTRK1   Yes 
Lee S et al, 2015 [8] TPM3-NTRK1   Yes TPM3-NTRK1   Yes 
Amatu et al. 2015 [9]  CAD-ALK  Yes 
Park et al. 2016 [10] 
LMNA-NTRK1   No, stage II 
TPM3-NTRK1   No, stage III 
TPM3-NTRK1   No 
Yakirevich et al. 2016 [11] 
 STRN-ALK  Yes 
 CENPF-ALK  Yes 
 MAPRE3-ALK  Yes 
 EML4-ALK  Yes 
 PRKAR1B-
ALK 
 Yes 
Hechtman et al. 2016 [12] ETV6-NTRK3   Yes 
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Supplementary Table S2. List of patients bearing ALK, ROS1, NTRK rearrangements with 
retrieving source, clinical center, identified gene fusion and NGS panel used. 
Patient Retrieving source Clinical center Gene Fusion NGS panel 
#1 Ignyta Inc. SMC, South Korea TPM3-NTRK1 Minerva panel 
#2 Ignyta Inc. SMC, South Korea EML4-ALK Minerva panel 
#3 Ignyta Inc. SMC, South Korea TPM3-NTRK1 Minerva panel 
#4 Foundation Medicine, MA, USA SMC, South Korea CAD-ALK FMI panel 
#5 Foundation Medicine, MA, USA MSKCC, NYC, USA ETV6-NTRK3 FMI panel 
#6 MSKCC, NYC, USA MSKCC, NYC, USA LMNA-NTRK1 MSK-IMPACT 
#7 Foundation Medicine, MA, USA MSKCC, NYC, USA LMNA-NTRK1 FMI panel 
#8 Austin Health, Australia MAX study Investigators C2orf44-ALK Minerva panel 
#9 Austin Health, Australia MAX study Investigators Unknown-ROS1  Minerva panel 
#10 Austin Health, Australia MAX study Investigators SLC34A2-ROS1 Minerva panel 
#11 Ignyta Inc. NCC, Italy LMNA-NTRK1 Minerva panel 
#12 Ignyta Inc. NCC, Italy CAD-ALK Minerva panel 
#13 Ignyta Inc. INT, Italy SCYL3-NTRK1 Minerva panel 
#14 Ignyta Inc. INT, Italy TPM3-NTRK1 Minerva panel 
#15 Ignyta Inc. UHG, Belgium EML4-ALK Minerva panel 
#16 Foundation Medicine, MA, USA Unknown CENPF-ALK FMI panel 
#17 Foundation Medicine, MA, USA Unknown PRKAR1B-ALK FMI panel 
#18 Foundation Medicine, MA, USA Unknown TPM3-NTRK1 FMI panel 
#19 Foundation Medicine, MA, USA Unknown TPM3-NTRK1 FMI panel 
#20 Foundation Medicine, MA, USA Unknown EML4-ALK FMI panel 
#21 Foundation Medicine, MA, USA Unknown TPM3-NTRK1 FMI panel 
  
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#22 Foundation Medicine, MA, USA Unknown MAPRE3-ALK FMI panel 
#23 Foundation Medicine, MA, USA Unknown STRN-ALK FMI panel 
#24 Foundation Medicine, MA, USA Unknown CAD-ALK FMI panel 
#25 Foundation Medicine, MA, USA Unknown TPM3-NTRK1 FMI panel 
#26 Foundation Medicine, MA, USA Unknown GOPC-ROS1 FMI panel 
#27 Foundation Medicine, MA, USA Unknown ETV6-NTRK3 FMI panel 
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Supplementary Figure 1. Identification and characterization of a novel SCYL3-NTRK1 in a 
CRC sample. Panel A: Immunohistochemistry (IHC) staining of tissue from Patient #13 using a cocktail 
of pan-Trk, ROS1 and ALK antibodies and a single DAB detection system.  Strong staining intensity was 
seen in almost 100% of tumor nuclei indicating the elevated expression of at least one of the targeted 
proteins.  Panel B: NTRK1 FISH (Abnova  SPEC NTRK1) was performed on the same specimen and 
resulted in break-apart positivity for the NTRK1 gene in 100% of nuclei. Panel C: An RNA-based NGS 
assay using AMP-technology was performed to identify the fusion/fusion partner. This patient exhibited an 
intrachromosomal inversion and rearrangement that leads to a novel in-frame fusion of SCYL3 exon 11 to 
exon 12 of NTRK1 (upstream of the NTRK1 kinase domain in exons 13-17). Panel D: To confirm the novel 
fusion, RT-PCR was performed using primers specific to the SCYL3-NTRK1 gene rearrangement.  Lane a is 
a nucleic acid size ladder, annotated in base pair sizes by the column titled ‘Bp’; lane b is the RT-PCR 
product obtained from the patient specimen using rearrangement primers. The arrow indicates the specific 
RT-PCR product, which migrated at the expected 126 bp size; lane c is a no template control using the same 
primers as in lane b, which resulted in absence of a PCR product at the expected 126 bp (the strongest 
product generated migrates at 66 bp). 
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Supplementary Figure 2. Identification of gene fusions in TCGA colorectal cancer samples by 
outlier kinase analysis. Scatter-plot representation of transcriptional outlier kinases in TCGA CRC 
samples (N = 644). Grey coloured circles indicate 154 samples (listed in Supplemental Table S4) carrying 
outlier ALK, NTRK1, NTRK2, NTRK3, ROS1 gene expression, defined as the 95th percentile for each gene 
based on z-score normalization. Gene fusion identification in the RNA sequencing reads from these 154 
samples was performed by applying a custom pipeline (see Online Methods) and the FusionMap1 algorithm. 
A total of 7 fusions (red circles) in the selected kinases were found. 
 
 
 
 
1. Ge, H., et al. FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. 
Bioinformatics 27, 1922-1928 (2011). 
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Supplementary Figure 3. Putative fusion diagrams for each TCGA CRC sample based on 
publicly available RNA sequencing data.  All fusions include the ALK or NTRK3 full tyrosine kinase 
domain (shown in purple), with the exception of sample TCGA-A6-2674, in which only a portion of the 
kinase domain was retained. Genomic partner (depicted in blue) is on the left and tyrosine kinase receptor is 
on the right. Arrows indicate the direction of transcription for each gene. Chromosomes and exons (ex) are 
also indicated.  1, PRKAR1A–ALK fusion containing a portion of the PRKAR1A regulatory subunit of type 
II PKA R-subunit (RIIa). 2, EML4–ALK fusion containing the EML4 Hydrophobic EMAP-like protein 
(HELP) motif and a portion of the WD40 domain. 3, PPP4R3B–ALK fusion containing also the 
meprin/A5/mu (MAM) and the transmembrane (TM) domains of ALK. 4, ETV6–NTRK3 fusion. 5, 
COX5A-NTRK3 fusion. 6, ETV6–NTRK3 fusion. 7, VPS18-NTRK3 fusion, in which only a portion of the 
kinase domain of NTRK3 is retained. Other abbreviations are as follows: PP4R3B, protein phosphatase 4 
regulatory subunit 3B; SAM, Sterile alpha motif (SAM)/Pointed domain; HELP, Hydrophobic EMAP-Like 
Protein motif WD, WD40 repeat (also known as the beta-transducin repeat); WH1, WASp Homology 
domain 1; MAM, meprin/A5/mu domain; TM, transmembrane domain.  
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Supplementary Figure 4. Survival in metastatic colorectal cancer patients in subgroups defind 
by ALK, ROS1, NTRK rearrangements and primary tumor location. Kaplan-Meier curves for 
overall survival (OS) in patients with left-sided primary and ALK, ROS1, NTRK rearranged tumors 
(n=4; light blue line) as compared to those with left-sided primary and ALK, ROS1, NTRK negative 
tumors (n=216; orange line) and in patients with right-sided primary and ALK, ROS1, NTRK 
rearranged tumors (n=16; blue line) as compared to those with right-sided primary and ALK, ROS1, 
NTRK negative tumors (n=96; red line). 
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Supplementary Figure 5. Summary of the clinical history of the four patients (N°1, 11, 13 and 
14) evaluable for response to anti-EGFR monoclonal antibodies (cetuximab or 
panitumumab). Shaded boxes indicate periods of administration of the indicated chemotherapeutic agents. 
Blue vertical lines indicate timing of tumor specimen acquisition from surgical procedures or biopsy, as well 
as dates of tumor assessment by radiological imaging. As shown, all evaluable patients had progressive 
disease to anti-EGFR-based therapy.  
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Supplementary Figure 6. Summary of the clinical history and immunohistochemical study of 
the patient (N°15) responding to immune checkpoint inhibition. Panel A. Summary of the clinical 
history of the patient with EML4-ALK fusion and MMR deficient status (N°15) receving anti-PD-1 
immunotherapy with nivolumab. Shaded boxes indicate periods of administration of the indicated 
chemotherapeutic agents. Blue vertical lines indicate timing of tumor specimen acquisition from surgical 
procedures or biopsy, as well as dates of tumor assessment by radiological imaging. As shown, the patients 
had partial response to anti-PD-1 which is still ongoing. Panel B. Positive immunohistochemical staining for 
CD4. Panel C. Positive immunohistochemical staining for CD8. Panel D. Positive immunohistochemical 
staining for CD68. Panel E. Positive immunohistochemical staining for PD-L1 in >50% of tumor cells.  
 
 
  
14 
 
Supplementary References 
 
1 Murphy DA, Ely HA, Shoemaker R., et al. Detecting Gene Rearrangements in Patient 
Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment 
Followed by Sensitive Next-Generation Sequencing. Appl Immunohistochem Mol Morphol 
2016; https://dx.doi.org/10.1097/PAI.0000000000000360 published online Mar 29. 
2 Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-
generation sequencing. Nat Med 2014;20:1479-84. 
3 Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in 
first-line treatment of metastatic colorectal cancer: results of the Australasian 
Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010;28: 
3191-8. 
4 Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical 
cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 
2013; 31:1023-31. 
5 Hall, M.J., et al. Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) 
tumor samples tested with comprehensive genomic profiling (CGP). J Clin Oncol 2016; 34 
(suppl 4S) abstr 528. 
6 Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation 
Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based 
Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol 
Diagn 2015;17:251-64. 
7 Kothari V, Wei I, Shankar S, et al. Outlier kinase expression by RNA sequencing as targets 
for precision therapy. Cancer Discov 2013;3:280-93. 
8 Medico E, Russo M, Picco G, et al. The molecular landscape of colorectal cancer cell lines 
unveils clinically actionable kinase targets. Nat Commun 2015;6:7002. 
9 Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. 
Bioinformatics 2010;26:589-95. 
10 Kent WJ. BLAT--the BLAST-like alignment tool. Genome Res 2002; 12:656-64. 
11 Ge H, Liu K, Juan T, Fang F, Newman M, Hoeck W. FusionMap: detecting fusion genes 
from next-generation sequencing data at base-pair resolution. Bioinformatics 2011;27:1922-
8. 
12 Yoshihara K, Wang Q, Torres-Garcia W, et al. The landscape and therapeutic relevance of 
cancer-associated transcript fusions. Oncogene 2015;34:4845-54. 
 
 
 
 
